 |
|
|
|
 |
|
|
| Article 1 to 10 out of 42 concerning Dyax Corp.
|
-
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
(12 Feb 2009)
Dyax Corp. and Fovea Pharmaceuticals, SA announced that they have entered into an exclusive license agreement for the development and commercialization of an ocular formulation of DX-88 for the treatment of retinal diseases.The license grants Fovea ...
-
Dyax Announces Expansion of Antibody Discovery Collaboration with Biogen Idec
(09 Feb 2009)
Dyax Corp. announced that they have expanded their antibody funded research and library license agreement with Biogen Idec to include the discovery of additional antibody products identified using Dyax’s proprietary drug discovery technology, phage ...
-
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
(06 Feb 2009)
Dyax Corp. announced that the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Advisory Committee voted (6 yes, 5 no, 2 abstentions) in favor of approval of DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema ...
-
FDA Accepts Filing and Grants Priority Review for Dyax' DX-88 for Hereditary Angioedema
(26 Nov 2008)
Dyax Corp. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Biologics License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) and has ...
-
Dyax Announces CEO Transition Plan
(22 Oct 2008)
Gustav A. Christensen to Succeed Henry E. Blair as President and CEO on January 1, 2009
Dyax Corp. announced that Gustav A. Christensen, who joined Dyax as Executive Vice President and Chief Business Officer in April 2007, will succeed Henry E. Blair as President and Chief Executive Officer on January 1, 2009. Mr. Blair, who co-founded ...
-
Dyax Announces Completion of Biologics License Application for DX-88 for Hereditary Angioedema
(29 Sep 2008)
Dyax Corp. announced the completion of its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for approval of Dyax's lead product candidate DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE). Dyax ...
-
Dyax Announces Final Patient Treated in Second Phase 3 Clinical Trial (EDEMA4) of DX-88 in Hereditary Angioedema
(26 Jun 2008)
Company's Clinical Research Provider, BattelleCRO, to Shut Down
Dyax Corp. announced that it has treated the final patient in its second Phase 3, 96-patient trial of DX-88, known as EDEMA4, for the treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare and life-threatening inflammatory ...
-
Dyax Corp. Announces Intent to Close Belgium Research Facility
(30 Apr 2008)
Dyax Corp. announced that the Board of Directors of its Belgian subsidiary, Dyax SA, has initiated discussions with its 24 employees as it considers a possible closure of the Liege-based research facility. The closure option would allow for ...
-
Dyax Corp. and Cubist Pharmaceuticals, Inc. Sign Development and Commercialization Agreement for DX-88 Surgical Indications
(28 Apr 2008)
Dyax Corp. and Cubist Pharmaceuticals, Inc. announced that they have signed an exclusive license and collaboration agreement for the development and commercialization of the intravenous formulation of DX-88 for the prevention of blood loss during ...
-
Dyax Corp. Announces First Market Approval from Licensing and Funded Research Program
(03 Mar 2008)
Peptide ligand used in purification process during manufacture of Wyeth's XYNTHA
Dyax Corp. announced that Wyeth Pharmaceuticals, a division of Wyeth, recently received market approval from the U.S. Food and Drug Administration for XYNTHA(TM) (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free), a recombinant factor VIII ...
Additional information
Dyax Corp.
Cambridge, MA, USA
Company
|
|
|
|
|
|
Top
